Benitec Biopharma (BNTC) Accumulated Depreciation & Amortization (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $52000.0 as the latest value for Q1 2025.
- Quarterly Accumulated Depreciation & Amortization fell 14.75% to $52000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $52000.0 through Mar 2025, down 14.75% year-over-year, with the annual reading at $87000.0 for FY2024, 36.03% down from the prior year.
- Accumulated Depreciation & Amortization hit $52000.0 in Q1 2025 for Benitec Biopharma, up from $39000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $231000.0 in Q2 2021 to a low of $17000.0 in Q4 2023.
- Historically, Accumulated Depreciation & Amortization has averaged $83176.5 across 5 years, with a median of $55000.0 in 2021.
- Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 79.52% in 2023 and later soared 129.41% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $55000.0 in 2021, then soared by 50.91% to $83000.0 in 2022, then tumbled by 79.52% to $17000.0 in 2023, then skyrocketed by 129.41% to $39000.0 in 2024, then skyrocketed by 33.33% to $52000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for BNTC at $52000.0 in Q1 2025, $39000.0 in Q4 2024, and $25000.0 in Q3 2024.